ZOVOO
10.12.2021 09:28:14 CET | Business Wire | Press release
ZOVOO , founded in 2019 and emerging as a dark horse in the electronic cigarette industry, recently launched its latest product Dragbar and achieved a sales milestone of over 1,000,000 pieces in the global market in less than one month, fully demonstrating the extraordinary strength of ZOVOO .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005123/en/
User-oriented and differentiated to meet market demand
According to ZOVOO' s global sales analysis, ZOVOO had an impressive performance in Southeast Asia, North America and Europe, which is attributable to not only Dragbar' s excellent capability, but also the ZOVOO team's in-depth and detailed market analysis of different regions.
Dragbar' s innovation and research team employed polymer fibers and ergonomic lip sensation design to address the consumers' most-concerned issues such as oil leakage and dry hit, while also ensuring the taste and recovery of the product. Using the most popular double injection molding process and the collision of extremely vibrant colors, the high-quality product is aesthetically attractive and tasteful, and soon gained the recognition of the consumers.
Product preference varies in different markets, so the team made in-depth investigations on product appearances and sizes and provided different series of Dragbar to cater to users in different regions, eventually achieving sales performance that was in line with the target of the ZOVOO team.
Creating amazing products with extreme craftsmanship
The ZOVOO design team, with its decade-long history, consists of senior creative elites, concept artists, visual designers and technical engineers. As ZOVOO 's first product for the overseas market, Dragbar cost the design team a whole year to finish. Even after thousands of adjustments, tests, and appearance improvements, the team did not start mass production until it was 100% confident with the final product.
In addition, since the founding of ZOVOO , the team has been focused on technology, constantly making breakthroughs and pursuing new patents and new technologies. During the long process ranging from research and development to design, production, and testing before the launch of each product, the innovation and research team is particular about every detail of the product, so as to bring comfortable and safe experience to the consumers.
Dragbar' s sales volume of 1,000,000 pieces achieved in a short period of time fully demonstrated the ZOVOO team's accurate insight into the users' needs, its excellent research and development capabilities, as well as its forward-looking product design strength. With the excellent performance of Dragbar, ZOVOO has successfully entered markets in more than 50 countries and regions in North America, Europe and Southeast Asia. In the future, the ZOVOO team will continue to develop new products in line with market trends to meet the users' new needs.
About ZOVOO
ZOVOO has established strategic partnerships with ICCPP manufacturers on a basis of mutual trust. ZOVOO enables its sustainable supply chain management by supporting safety standards, social values and environment-friendliness. With the motto of "Creating is Endless", ZOVOO is committed to adding inspirations to the colorful life of people with technology, and seeking partners globally to better serve the consumers.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical. The product is only intended for adult smokers of legal purchase age.
ZOVOO Official Website: https://www.izovoo.com/
IG: https://www.instagram.com/zovoo_tech/
Facebook: https://www.facebook.com/zovootechofficial
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005123/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom